Program Schedule

Factors Associated with Pre-season Seroprotection to B Lineage Influenza Viruses in Children

Session: Poster Abstract Session: Vaccines: Influenza
Friday, October 10, 2014
Room: The Pennsylvania Convention Center: IDExpo Hall BC
  • IDSA_Baseline B seroprotection.pdf (359.0 kB)
  • Background: Few studies have examined the duration of immune response against B lineage influenza viruses in relation to prior vaccination and/or influenza infection. We examined factors associated with seroprotective antibody titers in fall 2013 among children 5-17 years old with known influenza vaccination and infection status from the previous season.

    Methods: Serum was drawn from 163 children prior to 2013-14 influenza vaccination, including 53 (33%) with PCR-confirmed B lineage infection in 2012-13, 91 (56%) who received the 2012-13 vaccine (Yamagata lineage) and 21 (13%) who were both vaccinated and infected. Antibody titers were measured by hemagglutination-inhibition (HI) assays for both influenza B lineage strains licensed for use in the 2013-14 vaccines. The association between seroprotective titer (≥1:40) and prior vaccine exposure or infection was examined in a modified Poisson regression model. Potential predictors included age, prior vaccine receipt, number of lineage specific vaccines received in the past 5 seasons, and lineage specific B infection in the prior season. Titers were analyzed separately for B/Yamagata and B/Victoria. 

    Results: Of 163 children, 96 (59%) had seroprotective titers for B/Victoria, 106 (65%) had seroprotective titers for B/Yamagata, and 73 (45%) had seroprotective titers for both viruses; 22 (13%) had been infected with B/Yamagata and 31 (19%) with B/Victoria in 2012-13.  Vaccination in the 2012-13 season and ≥1 dose of B/Yamagata containing vaccine in the past 5 seasons were significantly associated with seroprotective titers for B/Yamagata in univariate analyses; prior infection was not significant.  In the multivariate model, only 2012-13 vaccine receipt was significantly associated with a seroprotective titer for B/Yamagata (RR 1.5, 95%CI 1.2-1.9).  A seroprotective titer for B/Victoria was independently associated with receipt of 2012-13 vaccine (RR 1.4, 95%CI 1.1-1.8) and with B/Victoria infection the 2012-13 season (RR 1.4, 95%CI 1.1-1.8) in the multivariate analysis.

    Conclusion: Prior vaccine receipt is an important determinant of seroprotective titers for both B lineages in children. Prior receipt of B/Yamagata vaccine was associated with heterologous titers to B/Victoria.

    Jennifer King, MPH1, Huong Mclean, MPH, PhD1, Maria Sundaram, MSPH1, Jennifer Meece, PhD2, Sarah Spencer, Ph.D.3, Jin Hyang Kim, PhD3, Thomas Friedrich, PhD4, Brendan Flannery, PhD3, Alicia M. Fry, MD, MPH3 and Edward Belongia, MD1, (1)Center for Clinical Epidemiology and Population Health, Marshfield Clinic Research Foundation, Marshfield, WI, (2)Integrated Research and Diagnositic Laboratory, Marshfield Clinic Research Foundation, Marshfield, WI, (3)Influenza Division, Centers for Disease Control and Prevention, Atlanta, GA, (4)Pathobiological Sciences, University of Wisconsin School of Veterinary Medicine, Madison, WI


    J. King, None

    H. Mclean, MedImmune, LLC: Grant Investigator, Research grant

    M. Sundaram, MedImmune, LLC: Project scientist on MedImmune-funded grant, Research grant

    J. Meece, None

    S. Spencer, None

    J. H. Kim, None

    T. Friedrich, None

    B. Flannery, None

    A. M. Fry, None

    E. Belongia, MedImmune, LLC: Grant Investigator, Research grant

    See more of: Vaccines: Influenza
    See more of: Poster Abstract Session

    Findings in the abstracts are embargoed until 12:01 a.m. EDT, Oct. 8th with the exception of research findings presented at the IDWeek press conferences.

    Sponsoring Societies:

    © 2014, All Rights Reserved.

    Follow IDWeek